| 35.98 1.57 (4.56%) | 08-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 45.53 |
1-year : | 50.99 |
| Resists | First : | 38.98 |
Second : | 43.65 |
| Pivot price | 35.04  |
|||
| Supports | First : | 31.43 |
Second : | 26.14 |
| MAs | MA(5) : | 33.95 |
MA(20) : | 36.24 |
| MA(100) : | 28.74 |
MA(250) : | 24.43 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 32.3 |
D(3) : | 21.1 |
| RSI | RSI(14): 55.4 |
|||
| 52-week | High : | 43.65 | Low : | 15.93 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NGNE ] has closed below upper band by 34.6%. Bollinger Bands are 19.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 36.36 - 36.54 | 36.54 - 36.69 |
| Low: | 33.94 - 34.14 | 34.14 - 34.32 |
| Close: | 35.65 - 35.98 | 35.98 - 36.28 |
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Mon, 03 Aug 2026
NGNE|Neurogene Inc|Price:34.380|Chg%:+1.510 - TradingKey
Sat, 01 Aug 2026
Neurogene Inc. Revenue Breakdown – NASDAQ:NGNE - TradingView
Fri, 31 Jul 2026
NGNE|Neurogene Inc|Price:33.490|Chg%:-0.170 - TradingKey
Tue, 07 Jul 2026
Form 4 Neurogene Inc For: 7 July By Investing.com - Investing.com Nigeria
Mon, 06 Jul 2026
Neurogene lures 6 new hires with stock options tied to July 6 close - Stock Titan
Wed, 01 Jul 2026
Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome - Slideshow - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 20 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 7 (%) |
| Held by Institutions | 88.4 (%) |
| Shares Short | 2,930 (K) |
| Shares Short P.Month | 3,550 (K) |
| EPS | -4.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.22 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -24 % |
| Return on Equity (ttm) | -37.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -4.13 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -83 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -7.91 |
| PEG Ratio | 0 |
| Price to Book value | 2.36 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|